drugset / Trial / NCT04841148
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Phase 2
Recruiting
96 enrolled
Abramson Cancer Center at Penn Medicine
Breast Cancer Research Foundation · collabJohns Hopkins University · collabPfizer · collabTranslational Breast Cancer Research Consortium · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2027-07
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | HCQ | Unknown | 600 mg | — |
| Subject | Palbociclib | Small molecule | 75 mg | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |